Antimicrobial Drugs and Community-acquired Clostridium Difficile-associated Disease, UK

Overview

Journal Emerg Infect Dis

Specialty Infectious Diseases

Date 2007 Jun 8

PMID 17553260

Citations 16

Authors

J A Chris Delaney

Sandra Dial

Alan Barkun

Samy Suissa

Affiliations

Soon will be listed here.

Abstract

In a population-based case-control study of community acquired Clostridium difficile-associated disease (CDAD), we matched 1,233 cases to 12,330 controls. CDAD risk increased 3-fold with use of any antimicrobial agent and 6-fold with use of fluoroquinolones. Prior use of antimicrobial agents did not affect risk for CDAD after 6 months.

Citing Articles

Systemic Absorption of Oral and Rectal Vancomycin in a Critically Ill Patient: A Case Report.

Rakocevic R, Guevarra K Cureus. 2025; 16(12):e76008.

PMID: 39835081 PMC: 11743422. DOI: 10.7759/cureus.76008.

Evaluation of anti-infective-related -associated colitis using the Japanese Adverse Drug Event Report database.

Nakao S, Hasegawa S, Shimada K, Mukai R, Tanaka M, Matsumoto K Int J Med Sci. 2020; 17(7):921-930.

PMID: 32308545 PMC: 7163355. DOI: 10.7150/ijms.43789.

Cationic Anthraquinone Analogs as Selective Antimicrobials.

Subedi Y, Chang C Microbiol Insights. 2019; 12:1178636119847809.

PMID: 31205416 PMC: 6537284. DOI: 10.1177/1178636119847809.

Epidemiology and Risk Factors for Community-Associated Clostridium difficile Infection: A Narrative Review.

Bloomfield L, Riley T Infect Dis Ther. 2016; 5(3):231-51.

PMID: 27370914 PMC: 5019973. DOI: 10.1007/s40121-016-0117-y.

Doxycycline and Tigecycline: Two Friendly Drugs with a Low Association with Clostridium Difficile Infection.

Hung Y, Lee J, Lin H, Liu H, Wu Y, Tsai P Antibiotics (Basel). 2016; 4(2):216-29.

PMID: 27025622 PMC: 4790331. DOI: 10.3390/antibiotics4020216.

References

Freeman J, ONeill F, Wilcox M . Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother. 2003; 52(1):96-102. DOI: 10.1093/jac/dkg267. View

Blais L, Ernst P, Suissa S . Confounding by indication and channeling over time: the risks of beta 2-agonists. Am J Epidemiol. 1996; 144(12):1161-9. DOI: 10.1093/oxfordjournals.aje.a008895. View

Dhalla I, Mamdani M, Simor A, Kopp A, Rochon P, Juurlink D . Are broad-spectrum fluoroquinolones more likely to cause Clostridium difficile-associated disease?. Antimicrob Agents Chemother. 2006; 50(9):3216-9. PMC: 1563507. DOI: 10.1128/AAC.00592-06. View

Dial S, Delaney J, Barkun A, Suissa S . Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2006; 294(23):2989-95. DOI: 10.1001/jama.294.23.2989. View

McDonald L, Owings M, Jernigan D . Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003. Emerg Infect Dis. 2006; 12(3):409-15. PMC: 3291455. DOI: 10.3201/eid1205.051064. View

Horwitz R, Feinstein A . The problem of "protopathic bias" in case-control studies. Am J Med. 1980; 68(2):255-8. DOI: 10.1016/0002-9343(80)90363-0. View

McDonald L, Killgore G, Thompson A, Owens Jr R, Kazakova S, Sambol S . An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med. 2005; 353(23):2433-41. DOI: 10.1056/NEJMoa051590. View

Spencer R . The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother. 1998; 41 Suppl C:21-7. DOI: 10.1093/jac/41.suppl_3.21. View

Dubberke E, Reske K, McDonald L, Fraser V . ICD-9 codes and surveillance for Clostridium difficile-associated disease. Emerg Infect Dis. 2006; 12(10):1576-9. PMC: 3290935. DOI: 10.3201/eid1210.060016. View

10.

Loo V, Poirier L, Miller M, Oughton M, Libman M, Michaud S . A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005; 353(23):2442-9. DOI: 10.1056/NEJMoa051639. View

11.

Pepin J, Saheb N, Coulombe M, Alary M, Corriveau M, Authier S . Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis. 2005; 41(9):1254-60. DOI: 10.1086/496986. View

12.

Buchner A, Sonnenberg A . Epidemiology of Clostridium difficile infection in a large population of hospitalized US military veterans. Dig Dis Sci. 2002; 47(1):201-7. DOI: 10.1023/a:1013252528691. View

13.

Dial S, Delaney J, Schneider V, Suissa S . Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ. 2006; 175(7):745-8. PMC: 1569908. DOI: 10.1503/cmaj.060284. View

14.

Lawrenson R, Williams T, Farmer R . Clinical information for research; the use of general practice databases. J Public Health Med. 1999; 21(3):299-304. DOI: 10.1093/pubmed/21.3.299. View

15.

McCusker M, Harris A, Perencevich E, Roghmann M . Fluoroquinolone use and Clostridium difficile-associated diarrhea. Emerg Infect Dis. 2003; 9(6):730-3. PMC: 3000134. DOI: 10.3201/eid0906.020385. View